Novartis posts strong growth but warns of tough year ahead
pharmafile | January 27, 2011 | News story | Sales and Marketing | 2010 pharma results, Novartis
Novartis has posted strong sales growth for the full year but its chief executive warns of ‘headwinds in 2011’ as patent expiries start to bite.
Net sales for 2010 grew by an impressive 14% to $50.6 billion, buoyed by strong growth of its wet age-related macular degeneration drug Lucentis, which increased by 24% to $1.53bn.
Cancer drug Glivec also did well, growing by 8% to $4.27 billion for the full year, but Novartis faces will soon face the patent expiry of its biggest earner Diovan.
The blood pressure drug’s 2010 sales remained flat at $6.1 billion and Novartis is keen to offset the losses the lack of exclusivity will bring by diversifying its business model.
Moves towards this last year included its acquisition of Alcon, which made Novartis the world’s biggest ophthalmology company.
Novartis is also looking for future growth to come from its pipeline, which containing several dozen medicines with a number of potential blockbusters, including experimental respiratory drug QVA149.
The company has made a strong start to 2011, with the launch of its new oral multiple sclerosis drug Gilenya (fingolimod), predict reach $2.5 billion in peak year sales.
Given its strong pipeline and new launches, Novartis said it expected sales growth in its core pharma division is set reach the low- to mid-single digits this year.
Joseph Jimenez, chief executive of Novartis, said: “I am proud that Novartis continues to lead the industry in innovation, with 13 key product approvals and 16 major filings in pharmaceuticals in 2010, including our breakthrough multiple sclerosis therapy, Gilenya, which has been launched in the US.”
But Jimenez also warned of rough times ahead: “We are facing more headwinds in 2011 than in 2010 […] as this is the first year we are faced with patent expirations,” he told the Wall Street Journal.
“We expect, however, to offset the effect of these patent expirations. The fact that we expect to grow in 2011 is showing this.”
Ben Adams
Related Content
Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
